Personal relationships also played a role in moving the deal forward, with Apelian a long-time colleague of John G. McHutchison, who joined Gilead last year as senior vice president, liver disease therapeutics

Gilead Sciences Inc., of Foster City, Calif., added John G. McHutchison as senior vice president, liver disease therapeutics

John G. Cooper 307 0 307 0 436 743 0 0 DOR BIOPHARMA Evan Myrianthopoulos22 200 50 250 23 66 340 0 0 DURECT CORP Matthew J. Hogan 268 13 281 16 350 647 0 0 DYAX CORP George V. Migausky23 123 100 223 3 31 257 0 0 EMERGENT BIOSOLUTIONS R. Don Elsey 296 119 415 6 115 536 632 0 EMISPHERE TECHNOLOGIES Michael R. Garone 232 0 232 0 52 283 0 0 ENTREMED Dane R. Saglio 270 0 270 6 65 341 0 0 ENZO BIOCHEM Andrew R. Crescenzo 217 50

REPROS THERAPEUTICS INC 269 39 308 112 John G. Cooper DISCOVERY LABORATORIES INC 307 0 307 113 Paul J. Lytle PEREGRINE PHARMACEUTICLS INC 307 0 307 114 Jean-Frdric Viret ANESIVA INC 260 44 304 115 Matthew J. Pfeffer VAXGEN INC 304 0 304 116 Thomas H. Aasen ACADIA PHARMACEUTICALS INC 302 0 302 117 James A. McNulty BIODELIVERY SCIENCES INTL 202 100 302 118 Richard D. Katz ICAGEN INC 300 0 300 119 S. Colin Neill PHARMOS CORP 300 0 300 120 Ryan D

John G. Cooper 292 150 442 7 550 1,000 - - DOR BIOPHARMA Evan Myrianthopoulos23 200 50 250 27 146 324 - - DURECT Matthew J. Hogan 253 70 323 13 237 574 - - DYAX Stephen S. Galliker 301 47 348 - 122 470 - - EMERGENT BIOSOLUTIONS R. Don Elsey 272 91 364 7 132 503 - - EMISPHERE TECHNOLOGIES Michael R. Garone24 231 - 231 - 21 100 - - ENTREMED Dane R. Saglio 240 60 300 7 50 357 - - ENZO BIOCHEM Barry W. Weiner 434 225 659 65

John G. Cooper DISCOVERY LABORATORIES INC 292 150 442 53 Matthew K. Fust JAZZ PHARMACEUTICALS INC 340 100 440 54 Paul McBarron CYCLACEL PHARMACEUTICALS 324 107 432 55 John Poyhonen SENOMYX INC 288 141 430 56 Daniel M. Junius IMMUNOGEN INC 330 98 428 57 James E. Fickenscher AUXILIUM PHARMACEUTICALS INC 296 127 423 58 Stuart Grant BIOCRYST PHARMACEUTICALS INC 382 39 422 59 Stephen R. Davis NEUROGEN CORP 353 65 418 60 Mark G. Foletta AMYLIN

In 2006, the biotech gained access to as much as $50 million over a three-year period (it expires in May), and it signed a deal earlier this year to secure up to $60 million in funding, as needed. (See BioWorld Today, July 12, 2004, and May 28, 2008.) About $55 million remains from an earlier 2008 agreement, said John G. Cooper, Discovery Labs' executive vice president and chief financial officer

John G. Curd NOVACEA INC 312 71 383 97 David M. Floyd PHARMACOPEIA INC 286 90 376 98 Phil Skolnick DOV PHARMACEUTICAL INC 344 30 374 99 William P. Forbes SALIX PHARMACEUTICALS LTD 268 105 373 100 Emil D. Kakkis BIOMARIN PHARMACEUTICAL INC 290 82 372 101 Calvin B. Harley GERON CORP 282 89 371 102 Roman Chicz ANTIGENICS INC/DE 285 86 370 103 Ralph A. Eatz IMMUCOR INC 369 0 369 104 Charles R. Cantor SEQUENOM INC 294 74 369 105 Roger Mills

Company Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Value Realizable On Exercise Of Options ($000) Value Realized On Vesting Of Restricted Stock ($000) AASTROM BIOSCIENCES INC Janet M. Hock 218 15 233 0 0 233 0 0 ACADIA PHARMACEUTICALS Roger Mills 335 31 365 0 62 262 0 0 ACCELRYS INC Mathew A. Hahn (1) 351 56 407 6 322 574 0 0 ACCESS PHARMACEUTICALS David P. Nowotnik 254 20 274 7

John G. Cooper 292 120 412 8 558 977 0 0 DOR BIOPHARMA Evan Myrianthopoulos 196 55 251 49 103 403 0 0 DURECT CORP Matthew J. Hogan 250 20 270 4 44 146 0 0 DUSA PHARMA INC Richard C. Christopher 185 61 246 10 92 348 0 0 DYADIC INTERNATIONAL INC Wayne Moor 207 0 207 0 0 207 0 0 DYAX CORP Stephen S. Galliker 290 92 382 0 136 518 0 0 DYNAVAX TECHNOLOGIES Deborah A. Smeltzer 275 98 373 0 267 641 0 0 EMERGENT BIOSOLUTIONS R. Don

John G. Cooper DISCOVERY LABORATORIES INC 292 120 412 61 Louis A. Bianco CELL THERAPEUTICS INC 330 79 409 62 Julia P. Gregory LEXICON PHARMACEUTICALS INC 329 80 409 63 Ronald H. Spair ORASURE TECHNOLOGIES INC 320 88 408 64 Ward H. Wolff NUVELO INC 356 50 406 65 Robert Forrester COMBINATORX INC 270 135 405 66 Richard J. Moran GENTA INC 305 100 405 67 Brian A. Davis NEOSE TECHNOLOGIES INC 249 155 404 68 John Hodgman INTERMUNE INC 314 88 402 69

John G. Goddard, global head and senior vice president of strategic planning and business development for London-based AstraZeneca plc, agreed that companies with assets are taking advantage of the competitive nature of drug development, and he warned it can have consequences

John G. Cooper 275 90 365 7 0 372 425 1,285 Discovery Partners Intl

367 0 367 68 John G. Cooper Discovery Laboratories Inc

John G. Conley (3) 22 0 22 130 0 152 0 0 Alteon Inc...John G. Cooper 240 100 340 7 157 504 1,459 2,538 Discovery Partners Intl Inc

279 63 342 80 John G. Cooper Discovery Laboratories Inc

John G. Cooper 203 85 288 6 0 294 406 4,144 Discovery Partners Intl

210 79 289 77 John G. Cooper Discovery Laboratories Inc

John G. Cooper (18) 192 60 252 0 0 252 150 142 Discovery Partners Intl